Navigation Links
Somanetics Receives 510(k) Clearance From the FDA to Expand Features on Its Vital Sync Monitor
Date:5/24/2010

TROY, Mich., May 24 /PRNewswire-FirstCall/ -- Somanetics Corporation (Nasdaq: SMTS) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand features on its Vital Sync™ bedside monitor and research data aggregation system.  The clearance allows for interface with a broader range of bedside devices, display of derived parameters of calculated clinical indices, and an automated events trigger to alert clinicians when patient parameters fall outside desired thresholds.

"We believe this new 510(k) supports our goal of providing monitoring technologies that help critical care clinicians simplify and manage the wealth of patient data involved in assessing and treating patients," said Bruce Barrett, Somanetics' president and chief executive officer.  "Connectivity and display of additional vital patient parameters provides clinicians with 'dash-board' patient data to help clinicians' decision making and delivery of bedside care."

Somanetics' Vital Sync system provides the clinician with a view of patient data at the point of care to help medical professionals detect deteriorating patient condition early.  The Vital Sync system allows the clinician to select specific patient data from an array of bedside devices and view the data on a single, time-synced display at the bedside.  This focuses the clinician on relevant and interrelated patient data to enhance treatment decisions and improve patient care.

"Expanded compatibility with body cooling and perfusion equipment provides a more comprehensive device package for our neonatal and pediatric intensive care customers where hypothermic and ECMO treatment are used," adds Henry Szymanski, Somanetics' senior marketing manager.  "In addition, the derived parameters and automated events features are expected to help clinicians transform individual patient metrics and events into more meaningful and actionable information."

About Somanetics

Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets the INVOS® Cerebral/Somatic Oximeter.  The INVOS System is the only commercially-available cerebral/somatic oximeter with labeling for improved outcomes after surgery in patients above 2.5 kg.  The INVOS System is the clinical reference standard in cerebral/somatic oximetry, with a 12-year market track record, more than 750 clinical references and implementation at approximately 800 U.S. hospitals.  Somanetics also develops, manufactures and markets the Vital Sync™ System, a device that integrates data from bedside devices into a single system for enhanced patient assessment and decision making, data management and data storage.  Somanetics supports its customers through a direct U.S. sales force and clinical education team.  Covidien markets INVOS System products in Europe, Canada, the Middle East and South Africa and Edwards Lifesciences represents INVOS System products in Japan.  For more information visit www.somanetics.com.


'/>"/>
SOURCE Somanetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
2. Somanetics Corporation To Release First Quarter 2010 Financial Results and Host Conference Call March 17, 2010
3. Somanetics Corporation to Release Fourth Quarter and Fiscal 2009 Financial Results and Host Conference Call January 21, 2010
4. Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University
5. LensAR Laser System(TM) Receives FDA Clearance for Use in Cataract Surgery
6. China Sky One Medicals CEO Receives Award For "Leadership Excellence In Innovation"
7. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
8. DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
9. ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
10. VetCentric Receives Vet-VIPPS Certification from NABP
11. Mylan Receives Approval for Generic Version of Zyban(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Which areas are going to grow at the fastest ... 2026, assessing data, trends, opportunities and prospects. Our ... the most lucrative areas in the industry and the ... forecasted sales across the all the major categories of ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body care ... announced the company had a successful visit to the 2017 ECRM Diet, Vitamin & ... that work in the nutritional, sports and health industries a chance to meet in ...
(Date:1/20/2017)... ... , ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality ... January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures ... its products to all clients at reasonable prices. At the ECRM trade show, it ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... to enhance people’s everyday lives, recently attended the January ECRM Trade Show in ... Science is known for its large range of supplements that keep the body ...
(Date:1/20/2017)... ... 2017 , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation ... trial has been life-saving as she has been on the trial for more ... diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year later ...
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
Breaking Medicine News(10 mins):